For instance, in melanoma and colorectal cancer, tumors harbouring K-RAS, H-RAS, N-RAS or B-RAF constitutively active mutations may be insensitive to ERK1/2 inhibitors. This evidence concerns the gene KRAS and colorectal cancer.